Table 2.
League table of of adverse events
| DFN-02 | 10.52 (0.54,203.3) | ||||||||||
| 1.16 (0.05,26.10) | Ket | 1.35 (0.45,4.00) | a16.93 (5.71,50.24) | ||||||||
| 1.51 (0.07,32.30) | 1.30 (0.37,4.56) | AVP-825 | 6.98 (3.14,15.54) | ||||||||
| 8.71 (0.40,187.8) | 7.52 (2.13,26.57) | 5.78 (1.85,18.09) | ROX-828 | 1.21 (0.54,2.73) | |||||||
| 4.48 (0.23,88.54) | 3.86 (1.42,10.53) | b2.97 (1.23,7.18) | 0.51 (0.21,1.26) | Suma10mg | 0.69 (0.49,0.99) | 2.15 (1.47,3.16) | |||||
| 2.91 (0.15,57.39) | 2.51 (0.96,6.60) | 1.93 (0.81,4.61) | 0.33 (0.14,0.81) | b0.65 (0.46,0.92) | Suma20mg | 3.61 (2.58,5.09) | |||||
| 5.15 (0.25,104.7) | 4.45 (1.46,13.50) | 3.42 (1.30,9.02) | 0.59 (0.22,1.58) | 1.15 (0.59,2.23) | 1.77 (0.93,3.37) | Zol2.5 mg | 0.63 (0.35,1.14) | 1.96 (1.05,3.62) | |||
| 3.11 (0.16,61.21) | 2.69 (0.97,7.43) | 2.07 (0.88,4.89) | 0.36 (0.15,0.85) | 0.70 (0.43,1.13) | 1.07 (0.67,1.70) | 0.61 (0.35,1.04) | Zol5mg | 3.38 (2.46,4.63) | |||
| 5.16 (0.26,102.5) | 4.46 (1.57,12.66) | 3.43 (1.40,8.37) | 0.59 (0.24,1.47) | 1.15 (0.70,1.99) | 1.77 (1.05,2.99) | 1.00 (0.51,1.98) | 1.66 (0.99,2.75) | Zave | 2.04 (1.37,3.03) | ||
| 1.09 (0.05,23.35) | 0.94 (0.27,3.27) | 0.72 (0.23,2.22) | 0.13 (0.04,0.39) | 0.24 (0.10,0.58) | 0.37 (0.16,0.88) | 0.21 (0.08,0.55) | 0.35 (0.15,0.82) | 0.21 (0.09,0.51) | DHE2mg | 9.65 (4.39,21.22) | |
| 7.54 (0.37,152.8) | 6.51 (2.16,19.62) | 5.01 (1.91,13.09) | 0.87 (0.33,2.29) | 1.68 (0.88,3.23) | 2.59 (1.38,4.88) | 1.46 (0.68,3.15) | 2.42 (1.30,4.50) | 1.46 (0.75,2.84) | 6.92 (2.67,17.91) | MAP0004 | 1.40 (0.82,2.38) |
| 10.51 (0.54,203.32) | a9.08 (3.46,23.86) | 6.98 (3.14,15.54) | 1.21 (0.54,2.73) | 2.35 (1.62,3.41) | 3.61 (2.57,5.07) | 2.04 (1.18,3.54) | 3.38 (2.46,4.63) | 2.04 (1.37,3.03) | 9.65 (4.39,21.22) | 1.40 (0.82,2.38) | Placebo |
Pairwise (upper-right portion) and network (lower-left portion) meta-analysis results are presented as estimated effect sizes for the adverse events. For the pairwise meta-analyses, outcomes are expressed as odds ratios (OR) with 95% credible interval (CI) (OR of > 1 indicated that the treatment specified in the row got more improvement than that specified in the column),0 < OR < 1, the opposite. For the network meta-analysis, OR of > 1 indicated that the treatment specified in the column got better improvement than that specified in the row, 0 < OR < 1, the opposite.95% CI that did not contain one was considered to have a statistical difference
Bold results indicated statistical significance. aindicated a significant difference between direct and mixed comparisons. bindicated a significant difference between the basic model and sensitivity analysis
DFN-02, sumatriptan nose spray 10 mg with a permeation enhancer; Ket, ketorolac nose spray 31.5 mg; Suma10mg, sumatriptan nose spray 10 mg; Suma20mg, sumatriptan nose spray 20 mg; Zol2.5 mg, zolmitriptan nose spray 2.5 mg; Zol5mg, zolmitriptan nose spray 5 mg; Zave, zavegepant nose spray 10 mg; Buto, butorphanol nose spray 1 mg; AVP-825, a drug-device combination of 22 mg sumatriptan powder; MAP0004, a dihydroergotamine inhaler; ROX-828, ketorolac 31.5 mg with 6% of lidocaine; DHE, dihydroergotamine nose spray 2 mg